INHIBITION OF ALDOSE REDUCTASE IN A SIX MONTH OF ELEVATED SURAL NERVE WATER

六个月升高的腓肠神经水对醛糖还原酶的抑制

• 批准号: 5222043
• 负责人: R P EATON
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5222043
• 关键词: aldehyde reductase; biomarker; clinical research; clinical trials; diabetes mellitus; diabetic neuropathy; edema; human subject; human therapy evaluation; magnetic resonance imaging; nervous system disorder chemotherapy; neurophysiology; pathologic process; peripheral nervous system disorders

This project is directed at testing the hypothesis that diabetic sural nerve water represents a marker for increased aldose reductase flux, as an early and reversible step in the pathogenesis of diabetic neuropathy. We plan to administer an inhibitor of AR, Tolrestat, in a double blind fashion to 20 diabetic subjects with elevated nerve water and early neuropathy, and to follow the nerve water and neuropathy with MRI and neurophysiology testing to determine both the validity of the hypothesis & utility of AR inhibition as a therapy.

本项目旨在验证糖尿病患者腓肠神经 神经水代表增加的醛糖还原酶通量的标志物， 糖尿病神经病变发病机制中的早期和可逆步骤。 我们计划在一个双盲研究中， 对20名糖尿病患者进行了神经水升高和早期 神经病变，并通过MRI跟踪神经水和神经病变， 神经生理学测试以确定假设的有效性 AR抑制作为一种治疗的效用。